Enovis Corporation
ENOV Healthcare Medical Devices
Enovis Corporation’s revenue for fiscal 2025 (year ended December 2025) was $2.2 billion, up 6.66% from fiscal 2024. In the quarter to June 2026, revenue grew 3.23%, EPS grew 96.9%, free cash flow grew 815.8% and total debt fell 7.82%, each against the same quarter a year earlier. Revenue growth for five consecutive years; insiders bought in the last twelve months.
Follow ENOV
Enovis Corporation (ENOV) Piotroski F-score
Enovis Corporation's Piotroski F-score for fiscal 2025 is 4 out of 9: 4 of nine tests of profitability, leverage and efficiency passed, up from 3 in fiscal 2024.
Piotroski F-score, annual
Embed this chart
Annual newest first
| Period | Piotroski F-score | Change (points) |
|---|---|---|
| FY2025 | 4 | 1.00 |
| FY2024 | 3 | (2.00) |
| FY2023 | 5 | 2.00 |
| FY2022 | 3 | (5.00) |
| FY2021 | 8 | 1.00 |
| FY2020 | 7 | 2.00 |
| FY2019 | 5 | 0.00 |
| FY2018 | 5 | (2.00) |
| FY2017 | 7 | 1.00 |
| FY2016 | 6 | — |
How fiscal 2025’s score is made up
| Test | This year | Year before | Result | Points |
|---|---|---|---|---|
| Positive return on assets | (27.69%) | (17.89%) | Fail | 0 |
| Positive operating cash flow | 217.29m | 113.50m | Pass | 1 |
| Rising return on assets | (27.69%) | (17.89%) | Fail | 0 |
| Cash flow above net income | 1.40b | 939.00m | Pass | 1 |
| Falling long-term leverage | 0.30 | 0.28 | Fail | 0 |
| Rising current ratio | 2.02 | 2.17 | Fail | 0 |
| No new shares issued | 57,068,600 | 55,280,700 | Fail | 0 |
| Rising gross margin | 59.84% | 56.02% | Pass | 1 |
| Rising asset turnover | 0.53 | 0.46 | Pass | 1 |
| Piotroski F-score | Mixed | 4 | ||
How the Piotroski F-score works
One point for each of nine tests, this fiscal year against the one before: positive return on assets, positive operating cash flow, rising return on assets, cash flow above net income, falling long-term leverage, a rising current ratio, no new shares issued, a rising gross margin and rising asset turnover. The ratios are the ones on this site, so each can be checked.
Joseph Piotroski (2000) called 8–9 high and 0–1 low; reading it in three bands is the common convention:
| 7–9 | Strong — most fundamentals improved |
|---|---|
| 4–6 | Mixed |
| 0–3 | Weak — most fundamentals deteriorated |
Where this differs from the paper: return on assets is on average rather than beginning-of-year assets, and weighted basic shares stand in for shares issued. The score is shown only when all nine tests can be worked out, which takes three fiscal years; banks and insurers, which report no current assets or gross profit, have none.
Piotroski F-score against peers
| Company | Piotroski F-score |
|---|---|
| BVS Bioventus Inc. compare | 8 |
| AORT Artivion, Inc. compare | 7 |
| IRMD iRadimed Corporation compare | 6 |
| IART Integra LifeSciences Holdings Corporation compare | 5 |
| PRCT PROCEPT BioRobotics Corporation compare | 5 |
| ENOV Enovis Corporation | 4 |
| CBLL CeriBell, Inc. compare | 4 |
| TNDM Tandem Diabetes Care, Inc. compare | 3 |
| LMRI Lumexa Imaging Holdings, Inc. compare | — |
What Piotroski F-score is
The Piotroski F-Score tells an investor how many signs of improving profitability, funding and efficiency a company shows against a year earlier.
One point for each of nine tests against a year earlier: positive return on assets, positive operating cash flow, rising return on assets, cash flow above net income, falling long-term leverage, rising current ratio, no new shares issued, rising gross margin, and rising asset turnover